Peroxisome proliferator-activated receptor-γ antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines
JD Burton, ME Castillo, DM Goldenberg… - Anti-Cancer …, 2007 - journals.lww.com
Peroxisome proliferator-activated receptor-γ ligands have preclinical and clinical anticancer
activity. Most studies in this area address agonists, with relatively few reports on anticancer
effects of peroxisome proliferator-activated receptor-γ antagonists. Thus, we evaluated the
two pure peroxisome proliferator-activated receptor-γ antagonists, T0070907 and GW9662,
on a panel of hematopoietic and epithelial cell lines. The peroxisome proliferator-activated
receptor-γ antagonists and a reference agonist (pioglitazone) were tested in an in-vitro …
activity. Most studies in this area address agonists, with relatively few reports on anticancer
effects of peroxisome proliferator-activated receptor-γ antagonists. Thus, we evaluated the
two pure peroxisome proliferator-activated receptor-γ antagonists, T0070907 and GW9662,
on a panel of hematopoietic and epithelial cell lines. The peroxisome proliferator-activated
receptor-γ antagonists and a reference agonist (pioglitazone) were tested in an in-vitro …